tiprankstipranks
Trending News
More News >
BioRestorative Therapies (BRTX)
NASDAQ:BRTX
Advertisement

BioRestorative Therapies (BRTX) AI Stock Analysis

Compare
201 Followers

Top Page

BRTX

BioRestorative Therapies

(NASDAQ:BRTX)

Rating:48Neutral
Price Target:
BioRestorative Therapies faces significant financial challenges with ongoing net losses and negative cash flow, affecting its stock performance. However, recent improvements in financial metrics, substantial revenue growth, and promising clinical developments provide some optimism. Technical indicators suggest a neutral market position. Although valuation remains a concern due to the lack of profitability, the company's strategic focus on clinical trials and research offers potential for future growth.
Positive Factors
Efficacy of BRTX-100
The data release shows a significant improvement in function and pain for patients, indicating a positive trend for the efficacy of BRTX-100.
FDA Fast Track Designation
The company recently received Fast Track designation from FDA, which could expedite the approval process for its treatments.
Market Expansion
BRTX-100 has received IND clearance to move into a Phase 2 study for cervical spinal pain, potentially expanding its market and application.
Negative Factors
Financial Performance
The company reported a net loss of ($4.8M) and revenue of $25k.
Funding
The company has sufficient funding into 2026 with $10.7M in cash.

BioRestorative Therapies (BRTX) vs. SPDR S&P 500 ETF (SPY)

BioRestorative Therapies Business Overview & Revenue Model

Company DescriptionBioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.
How the Company Makes MoneyBioRestorative Therapies generates revenue through the development and commercialization of its proprietary cell and tissue-based therapeutic products. The company aims to earn revenue by advancing its clinical programs through various stages of regulatory approval, ultimately leading to product commercialization and sales. Key revenue streams include potential licensing agreements, strategic partnerships, and collaborations with pharmaceutical companies interested in its therapies. Additionally, BRTX may secure funding from grants and research subsidies as it progresses its clinical trials and expands its research initiatives. However, being a biotechnology company in the developmental stage, BioRestorative Therapies may also rely on equity financing and other forms of investment to support its operations until its therapies are fully developed and marketed.

BioRestorative Therapies Earnings Call Summary

Earnings Call Date:Aug 12, 2025
(Q2-2025)
|
% Change Since: 2.72%|
Next Earnings Date:Nov 18, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant revenue growth and promising clinical trial results, particularly for BRTX-100, alongside a strong financial position with no debt. However, these positives were tempered by an increased operational loss and uncertainty in future revenue projections from the BioCosmeceutical business. On balance, the achievements and progress in clinical trials and regulatory pathways suggest a positive outlook.
Q2-2025 Updates
Positive Updates
Significant Revenue Growth
Second quarter 2025 revenues were $303,000, representing an increase of 240% compared to $89,000 in the same period last year, primarily due to a contract manufacturing agreement on BioCosmeceuticals.
Improved Financial Position
The company ended the quarter with cash, cash equivalents, and marketable securities of $7.4 million and no outstanding debt.
Promising Clinical Trial Results
In the ongoing Phase II trial of BRTX-100, over 74% of subjects showed greater than 50% improvement in function, and over 72% reported greater than 50% reduction in pain by 52 weeks. No serious adverse events were reported.
Regulatory Progress and Enrollment
The company is more than halfway through enrollment for their 99-subject goal for the BRTX-100 trial and plans to meet with the FDA to accelerate the regulatory pathway.
Negative Updates
Increased Loss from Operations
The company's second quarter 2025 loss from operations was $3.3 million compared to $2.5 million for the comparable period of 2024.
Uncertain Revenue Forecast
There is uncertainty regarding future revenue trends from the BioCosmeceutical business, with no specific guidance provided for quarterly expectations.
Company Guidance
During the BioRestorative Therapies second quarter 2025 conference call, the company reported a significant 240% increase in revenue to $303,000, mainly driven by their contract manufacturing agreement in BioCosmeceuticals. Despite a loss from operations of $3.3 million, the net loss decreased to $2.7 million from $4 million in the prior year. Financially, the company ended the quarter with $7.4 million in cash and no outstanding debt. The ongoing Phase II trial of their lead candidate, BRTX-100, showed promising results, with over 74% of subjects experiencing greater than 50% improvement in function and over 72% reporting over 50% pain reduction by 52 weeks. Additionally, the company is advancing discussions with the FDA for a potential Type B meeting to expedite regulatory approval. BioRestorative is also exploring licensing opportunities for its ThermoStem metabolic disease programs and expanding its BioCosmeceutical platform.

BioRestorative Therapies Financial Statement Overview

Summary
BioRestorative Therapies is in a challenging financial position with consistent net losses and negative cash flows, despite some revenue growth. While the balance sheet shows reduced leverage and improved equity, the company's ability to generate cash and achieve profitability remains a significant concern. Continued focus on cost management and operational efficiency will be crucial for financial stability.
Income Statement
30
Negative
BioRestorative Therapies shows a significant increase in revenue year-over-year, but it remains small in absolute terms. Despite this, the company struggles with negative profitability metrics, including persistent net losses and negative EBIT and EBITDA margins, indicating ongoing operational challenges and high costs relative to revenue.
Balance Sheet
40
Negative
The company has improved its equity position with positive stockholders' equity, and it has no current total debt, reducing financial risk. However, the frequent large net losses impact the overall asset quality, and the equity ratio has been declining, signaling a need for better asset management.
Cash Flow
35
Negative
Operating cash flow has been consistently negative, reflecting ongoing cash outflows from operations. While free cash flow has seen slight improvement, it remains negative, indicating cash burn. The reliance on financing activities to support cash needs is evident, which may not be sustainable long-term without improved operational cash generation.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue391.00K401.00K145.80K119.80K46.00K77.00K
Gross Profit360.02K372.93K-19.93K119.80K46.00K77.00K
EBITDA-12.11M-11.37M-10.25M-18.85M-26.22M-9.48M
Net Income-12.10M-8.98M-10.42M-13.22M-44.30M-11.27M
Balance Sheet
Total Assets10.33M12.28M12.61M16.43M22.45M4.35M
Cash, Cash Equivalents and Short-Term Investments9.11M10.73M11.07M14.75M21.03M3.06M
Total Debt0.000.00162.32K301.64K670.70K4.79M
Total Liabilities4.18M3.75M2.61M6.14M856.50K5.68M
Stockholders Equity6.14M8.53M10.00M10.29M21.60M-1.33M
Cash Flow
Free Cash Flow-8.80M-8.34M-6.60M-6.31M-3.36M-1.96M
Operating Cash Flow-8.69M-8.23M-6.43M-5.87M-3.33M-1.96M
Investing Cash Flow7.81M514.53K3.25M-13.48M-30.66K0.00
Financing Cash Flow953.56K7.38M2.35M0.0021.32M5.03M

BioRestorative Therapies Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.51
Price Trends
50DMA
1.59
Negative
100DMA
1.67
Negative
200DMA
1.71
Negative
Market Momentum
MACD
-0.03
Negative
RSI
45.07
Neutral
STOCH
72.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRTX, the sentiment is Negative. The current price of 1.51 is above the 20-day moving average (MA) of 1.50, below the 50-day MA of 1.59, and below the 200-day MA of 1.71, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 45.07 is Neutral, neither overbought nor oversold. The STOCH value of 72.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BRTX.

BioRestorative Therapies Peers Comparison

Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
50
Neutral
AU$2.46B3.1310.94%2.67%36.93%13.84%
48
Neutral
$12.01M-137.09%247.62%-7.66%
42
Neutral
$11.51M-102.18%85.26%
41
Neutral
$15.91M-491.97%45.96%
41
Neutral
$31.18M-89.73%-100.00%-221.06%
40
Underperform
$15.70M-110.56%29.97%
34
Underperform
$10.35M-165.56%58.67%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BRTX
BioRestorative Therapies
1.51
-0.19
-11.18%
IMNN
Imunon
6.57
-9.86
-60.01%
MEIP
MEI Pharma
4.62
1.48
47.13%
PHIO
Phio Pharmaceuticals
2.07
-1.18
-36.31%
COCP
Cocrystal Pharma
1.51
-0.47
-23.74%
INAB
IN8bio
2.24
-13.81
-86.04%

BioRestorative Therapies Corporate Events

Regulatory Filings and Compliance
BioRestorative Clarifies Recent Press Release Details
Neutral
Mar 27, 2025

BioRestorative Therapies has released a statement clarifying that the information in their recent press release is being furnished and not filed, and will not be incorporated into any registration statement unless specifically identified. The company emphasizes that this does not constitute a determination or admission that the information is material or complete, nor should it be considered by investors for making investment decisions.

Regulatory Filings and Compliance
BioRestorative Therapies Issues Regulation FD Disclosure
Neutral
Feb 10, 2025

The news release does not contain specific information about BioRestorative Therapies’ industry, primary products or services, or market focus. The release appears to reference a Current Report on Form 8-K without providing substantial details about the company’s operations or implications for stakeholders.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 01, 2025